Key result
The Ross procedure in middle-aged adults demonstrated 10- and 15-year survival rates of 89% and 79%, respectively, with 86% freedom from autograft reintervention at 15 years.
Why the study?
Surgical options for aortic valve replacement in middle-aged adults are limited and suboptimal, making the Ross procedure a potential alternative whose long-term outcomes required description.
What are the long-term clinical and echocardiographic outcomes of the Ross procedure in middle-aged adults requiring aortic valve replacement?
Cohort (n=1,431)
Yes
What are the long-term clinical and echocardiographic outcomes of the Ross procedure in middle-aged adults requiring aortic valve replacement?
The Ross procedure demonstrates favorable long-term survival and freedom from reintervention in middle-aged adults, suggesting it is a viable alternative for aortic valve replacement in this population.
May support consideration in selected middle-aged adults; leaves open need for RCTs versus prosthetic AVR.
Surgical options for aortic valve replacement in middle aged adults are limited and suboptimal. The Ross (pulmonary autograft) procedure is potentially a good alternative in this patient population. We aimed to describe the long term clinical and echocardiographic outcome in middle aged adults who underwent the Ross procedure. An international multicenter study was conducted including consecutive patients of 18 to 65 years who underwent the Ross procedure between 1990 and 2016. Serial echocardiographic measurements of valve function were analyzed using non-linear mixed effects modeling. During the study period, 1431 patients (74.3% males) were operated at a median age of 48.5 years (inter quartile range 42.7-54.0), of which 1048 (73.2%) had a bicuspid aortic valve. Congenital heart disease was present in 1103 (77.1%) patients. Implantation techniques were root inclusion in 355 (24.9%), root replacement in 485 (34.0%) and subcoronary implantation in 587 (41.1%). Right ventricular outflow tract reconstruction was performed with homografts in 98.8% and bioprostheses in 1.2%. In hospital mortality was 10 (0.7%). Median follow up was 9.2 years (13015 total patient-years). Survival after 10 and 15 years was 89% and 79%, respectively. Freedom from allograft and autograft reintervention after 15 years were 91% and 86%, respectively. Late events were autograft endocarditis in 14 patients (0.11%/patient-year), homograft endocarditis in 11 patients (0.08%/patient-year) and stroke in 37 patients (0.3%/patient-year). Longitudinal peak gradient and regurgitation grades for both the pulmonary and aortic valve are shown in Figure 1.
No takes yet. Share an insight, caveat, or question.
Romeo et al. (2019) conducted a cohort in Aortic valve disease requiring replacement (n=1,431). Ross procedure was evaluated on Long term clinical and echocardiographic outcomes (survival and freedom from reintervention). The Ross procedure in middle-aged adults demonstrated 10- and 15-year survival rates of 89% and 79%, respectively, with 86% freedom from autograft reintervention at 15 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: